Lifestyle use of drugs by healthy people for enhancing cognition, creativity, motivation and pleasure
暂无分享,去创建一个
B. Sahakian | G. Savulich | Barbara J Sahakian | L-S Camilla d'Angelo | George Savulich | L. d'Angelo
[1] S. Colcombe,et al. Fitness Effects on the Cognitive Function of Older Adults: A Meta-Analytic Study—Revisited , 2018, Perspectives on psychological science : a journal of the Association for Psychological Science.
[2] J. Suckling,et al. Focusing the Neuroscience and Societal Implications of Cognitive Enhancers , 2017, Clinical pharmacology and therapeutics.
[3] A. Zalesky,et al. Abnormal white matter integrity in synthetic cannabinoid users , 2016, European Neuropsychopharmacology.
[4] J. Rossi,et al. Neurocognitive enhancement or impairment? A systematic meta-analysis of prescription stimulant effects on processing speed, decision-making, planning, and cognitive perseveration. , 2016, Experimental and clinical psychopharmacology.
[5] L. Clark,et al. Games in the Brain , 2016, The Neuroscientist : a review journal bringing neurobiology, neurology and psychiatry.
[6] A. Kjellgren,et al. The users of Novel Psychoactive Substances: Online survey about their characteristics, attitudes and motivations. , 2016, The International journal on drug policy.
[7] M. A. De Luca,et al. Neuropharmacology of New Psychoactive Substances (NPS): Focus on the Rewarding and Reinforcing Properties of Cannabimimetics and Amphetamine-Like Stimulants , 2016, Front. Neurosci..
[8] L. Parsons,et al. Keep off the grass? Cannabis, cognition and addiction , 2016, Nature Reviews Neuroscience.
[9] B. Sahakian,et al. Drugs, games, and devices for enhancing cognition: implications for work and society , 2016, Annals of the New York Academy of Sciences.
[10] M. Moyer. A Safe Drug to Boost Brainpower , 2016 .
[11] J. Ramsey,et al. Up: The rise of nitrous oxide abuse. An international survey of contemporary nitrous oxide use , 2016, Journal of psychopharmacology.
[12] Ruairidh M. Battleday,et al. Modafinil for cognitive neuroenhancement in healthy non-sleep-deprived subjects: A systematic review , 2016, European Neuropsychopharmacology.
[13] Christopher Southan,et al. The Concise Guide to PHARMACOLOGY 2015/16: Enzymes , 2015, British journal of pharmacology.
[14] Christopher Southan,et al. The Concise Guide to PHARMACOLOGY 2015/16: G protein‐coupled receptors , 2015, British journal of pharmacology.
[15] Christopher Southan,et al. The Concise Guide to PHARMACOLOGY 2015/16: Ligand‐gated ion channels , 2015, British journal of pharmacology.
[16] S. Martins,et al. Self-reported use of novel psychoactive substances in a US nationally representative survey: Prevalence, correlates, and a call for new survey methods to prevent underreporting. , 2015, Drug and alcohol dependence.
[17] Joanna L. Sharman,et al. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands , 2015, Nucleic Acids Res..
[18] G. Fond,et al. Innovative mechanisms of action for pharmaceutical cognitive enhancement: A systematic review , 2015, Psychiatry Research.
[19] John Suckling,et al. The impact of neuroscience on society: cognitive enhancement in neuropsychiatric disorders and in healthy people , 2015, Philosophical Transactions of the Royal Society B: Biological Sciences.
[20] M. Rossor,et al. Can we model a cognitive footprint of interventions and policies to help to meet the global challenge of dementia? , 2015, The Lancet.
[21] B. Sahakian,et al. The increasing lifestyle use of modafinil by healthy people: safety and ethical issues , 2015, Current Opinion in Behavioral Sciences.
[22] C. Hillman,et al. Physical activity, brain, and cognition , 2015, Current Opinion in Behavioral Sciences.
[23] R. Borschmann,et al. Risk of emergency medical treatment following consumption of cannabis or synthetic cannabinoids in a large global sample , 2015, Journal of psychopharmacology.
[24] Laura Orsolini,et al. Mind Navigators of Chemicals' Experimenters? A Web-Based Description of E-Psychonauts , 2015, Cyberpsychology Behav. Soc. Netw..
[25] F. Measham,et al. New psychoactive substances and British drug policy: A view from the cyber-psychonauts , 2015 .
[26] B. Sahakian,et al. Pharmacological cognitive enhancement: treatment of neuropsychiatric disorders and lifestyle use by healthy people. , 2015, The lancet. Psychiatry.
[27] J. Palamar,et al. Synthetic cannabinoid use in a nationally representative sample of US high school seniors. , 2015, Drug and alcohol dependence.
[28] Bas M. J. Olthof,et al. A survey of substance use for cognitive enhancement by university students in the Netherlands , 2015, Front. Syst. Neurosci..
[29] L. Orsolini,et al. Novel psychoactive substances of interest for psychiatry , 2015, World psychiatry : official journal of the World Psychiatric Association.
[30] Marilyn A Huestis,et al. Synthetic cannabinoids: epidemiology, pharmacodynamics, and clinical implications. , 2014, Drug and alcohol dependence.
[31] I. Singh,et al. Robust Resilience and Substantial Interest: A Survey of Pharmacological Cognitive Enhancement among University Students in the UK and Ireland , 2014, PloS one.
[32] Anna Richardson,et al. New psychoactive substances in England: a review of the evidence. , 2014 .
[33] T. Driscoll,et al. Pharmacological interventions for sleepiness and sleep disturbances caused by shift work , 2014, The Cochrane database of systematic reviews.
[34] Nora D Volkow,et al. Adverse health effects of marijuana use. , 2014, The New England journal of medicine.
[35] Angela Me,et al. World Drug Report 2014 , 2014 .
[36] M. Keshavan,et al. Cognitive training in mental disorders: update and future directions. , 2014, The American journal of psychiatry.
[37] P. Dargan,et al. The European Drug Emergencies Network (Euro-DEN) , 2014, Clinical toxicology.
[38] E. Hildt,et al. Life context of pharmacological academic performance enhancement among university students – a qualitative approach , 2014, BMC medical ethics.
[39] M. Liechti,et al. To Dope or Not to Dope: Neuroenhancement with Prescription Drugs and Drugs of Abuse among Swiss University Students , 2013, PloS one.
[40] P. Kardas,et al. [Prevalence, reasons, and forms of use of legal highs by internet-based survey participants]. , 2013, Psychiatria polska.
[41] Irena P. Ilieva,et al. Enhancement stimulants: perceived motivational and cognitive advantages , 2013, Front. Neurosci..
[42] John Suckling,et al. A positron emission tomography study of nigro-striatal dopaminergic mechanisms underlying attention: implications for ADHD and its treatment , 2013, Brain : a journal of neurology.
[43] D. D’Souza,et al. Spicing things up: synthetic cannabinoids , 2013, Psychopharmacology.
[44] F. Schifano,et al. “Spiceophrenia”: a systematic overview of “Spice”‐related psychopathological issues and a case report , 2013, Human psychopharmacology.
[45] B. Sahakian,et al. Bad Moves: How decision making goes wrong, and the ethics of smart drugs , 2013 .
[46] P. Simon,et al. Use of illicit and prescription drugs for cognitive or mood enhancement among surgeons , 2013, BMC Medicine.
[47] Barbara J. Sahakian,et al. Modafinil effects on cognition and emotion in schizophrenia and its neurochemical modulation in the brain , 2013, Neuropharmacology.
[48] T. Robbins,et al. Effects of modafinil on non-verbal cognition, task enjoyment and creative thinking in healthy volunteers , 2013, Neuropharmacology.
[49] Scott Vrecko. Just How Cognitive Is “Cognitive Enhancement”? On the Significance of Emotions in University Students' Experiences with Study Drugs , 2013, AJOB neuroscience.
[50] C. Davidson. New psychoactive substances , 2012, Progress in Neuro-Psychopharmacology and Biological Psychiatry.
[51] S. Gruber,et al. Age of onset of marijuana use and executive function. , 2012, Psychology of addictive behaviors : journal of the Society of Psychologists in Addictive Behaviors.
[52] Richie Poulton,et al. Persistent cannabis users show neuropsychological decline from childhood to midlife , 2012, Proceedings of the National Academy of Sciences.
[53] A. Darzi,et al. Effect of Pharmacological Enhancement on the Cognitive and Clinical Psychomotor Performance of Sleep-Deprived Doctors: A Randomized Controlled Trial , 2012, Annals of surgery.
[54] W. Hall,et al. Smart Drugs “As Common As Coffee”: Media Hype about Neuroenhancement , 2011, PloS one.
[55] M. E. Smith,et al. Are prescription stimulants "smart pills"? The epidemiology and cognitive neuroscience of prescription stimulant use by normal healthy individuals. , 2011, Psychological bulletin.
[56] W. Fratta,et al. Beyond THC: The New Generation of Cannabinoid Designer Drugs , 2011, Front. Behav. Neurosci..
[57] Europäische Kommission. Flash Eurobarometer 158 (Young people and drugs) , 2011 .
[58] B. Abler,et al. Neural Correlates of Error Monitoring Modulated by Atomoxetine in Healthy Volunteers , 2011, Biological Psychiatry.
[59] Suzanne Fergus,et al. Mephedrone (4-methylmethcathinone; ‘meow meow’): chemical, pharmacological and clinical issues , 2011, Psychopharmacology.
[60] I. Vardakou,et al. Drugs for youth via Internet and the example of mephedrone. , 2011, Toxicology letters.
[61] Karen McElrath,et al. Experiences with mephedrone pre- and post-legislative controls: perceptions of safety and sources of supply. , 2011, The International journal on drug policy.
[62] A. Winstock,et al. Mephedrone: still available and twice the price , 2010, The Lancet.
[63] P. Schlattmann,et al. Modafinil and methylphenidate for neuroenhancement in healthy individuals: A systematic review. , 2010, Pharmacological research.
[64] A. Dagher,et al. Effect of d-amphetamine on inhibition and motor planning as a function of baseline performance , 2010, Psychopharmacology.
[65] T. Klingberg. Training and plasticity of working memory , 2010, Trends in Cognitive Sciences.
[66] I. Heuser,et al. Acetylcholinesterase inhibitors and memantine for neuroenhancement in healthy individuals: a systematic review. , 2010, Pharmacological research.
[67] Martin Sarter,et al. Phasic acetylcholine release and the volume transmission hypothesis: time to move on , 2009, Nature Reviews Neuroscience.
[68] M. Talbot. Brain gain: the underground world of neuroenhancing drugs. , 2009, New Yorker.
[69] Young T. Hong,et al. Dopamine Release in Dissociable Striatal Subregions Predicts the Different Effects of Oral Methylphenidate on Reversal Learning and Spatial Working Memory , 2009, The Journal of Neuroscience.
[70] B. Sahakian,et al. The mental wealth of nations , 2008, Nature.
[71] M. Minzenberg,et al. Modafinil: A Review of Neurochemical Actions and Effects on Cognition , 2008, Neuropsychopharmacology.
[72] B. Maher,et al. Poll results: look who's doping , 2008, Nature.
[73] B. Sahakian,et al. Professor's little helper , 2007, Nature.
[74] T. Kelly,et al. Behavioral and subjective effects of d-amphetamine and modafinil in healthy adults. , 2007, Experimental and clinical psychopharmacology.
[75] R. Shelton,et al. A Randomized, Double-Blind, Crossover Trial of Modafinil on Mood , 2007, Journal of clinical psychopharmacology.
[76] S. McCabe,et al. Illicit Use of Specific Prescription Stimulants Among College Students: Prevalence, Motives, and Routes of Administration , 2006, Pharmacotherapy.
[77] T. Wilens. Mechanism of action of agents used in attention-deficit/hyperactivity disorder. , 2006, The Journal of clinical psychiatry.
[78] L. Johnston,et al. Monitoring the Future national survey results on drug use, 1975-2018: Volume II, college students and adults ages 19-60 , 2005 .
[79] L. Johnston,et al. Monitoring the Future national survey results on drug use, 1975-2017: Volume I, secondary school students , 2005 .
[80] Jonathan D. Cohen,et al. An integrative theory of locus coeruleus-norepinephrine function: adaptive gain and optimal performance. , 2005, Annual review of neuroscience.
[81] J. Caldwell,et al. Modafinil's effects on simulator performance and mood in pilots during 37 h without sleep. , 2004, Aviation, space, and environmental medicine.
[82] U. Müller,et al. Effects of modafinil on working memory processes in humans , 2004, Psychopharmacology.
[83] M. Feeley,et al. Effects of caffeine on human health , 2003, Food additives and contaminants.
[84] J. Sallis,et al. Effects of health-related physical education on academic achievement: project SPARK. , 1999, Research quarterly for exercise and sport.
[85] E. Gould,et al. Learning enhances adult neurogenesis in the hippocampal formation , 1999, Nature Neuroscience.
[86] G. Gigerenzer,et al. Specific attentional dysfunction in adults following early start of cannabis use , 1999, Psychopharmacology.
[87] P. Reuter. World drug report , 1998 .
[88] J. Olney,et al. Nitrous oxide (laughing gas) is an NMDA antagonist, neuroprotectant and neurotoxin , 1998, Nature Medicine.
[89] M. Gillman,et al. Clinical role and mechanisms of action of analgesic nitrous oxide. , 1998, The International journal of neuroscience.
[90] T. Robbins,et al. “Paradoxical” effects of psychomotor stimulant drugs in hyperactive children from the standpoint of behavioural pharmacology , 1979, Neuropharmacology.
[91] T. Robbins,et al. Are the effects of psychomotor stimulant drugs on hyperactive children really paradoxical? , 1977, Medical hypotheses.
[92] Matej Sande. Characteristics of the use of 3-MMC and other new psychoactive drugs in Slovenia, and the perceived problems experienced by users. , 2016, The International journal on drug policy.
[93] W. Hall. What has research over the past two decades revealed about the adverse health effects of recreational cannabis use? , 2015, Addiction.
[94] Patrick O'Malley,et al. Monitoring the Future national survey results on drug use, 1975-2018: Overview, key findings on adolescent drug use , 2015 .
[95] M. Evans-Brown,et al. New Psychoactive Substances in Europe. An Update from the EU Early Warning System , 2015 .
[96] F. Hickson,et al. The Chemsex study: drug use in sexual settings among gay and bisexual men in Lambeth, Southwark and Lewisham , 2014 .
[97] T. Robbins,et al. Brain science, addiction and drugs , 2010 .
[98] B. Christie,et al. Environmental enrichment and voluntary exercise massively increase neurogenesis in the adult hippocampus via dissociable pathways , 2006, Hippocampus.
[99] B. Sahakian,et al. Further analysis of the cognitive effects of tetrahydroaminoacridine (THA) in Alzheimer's disease: assessment of attentional and mnemonic function using CANTAB , 2005, Psychopharmacology.
[100] C. Ainsworth,et al. Brain gain. , 2001, New scientist.